MEDICURE COMPLETES TREATMENT IN THE PHASE II STUDY

Medicure, a cardiovascular drug discovery and development company, announced that the 16 week treatment period is complete for all patients in a Phase II matched study, which is evaluating the effects of Medicure's MC-4232 in patients with coexisting Type 2 diabetes and hypertension. The results of the matched trial, designed to demonstrate the clinical benefit of MC-4232 in the growing diabetic hypertensive patient population, are expected to be available in late summer.

The trial is a randomized, double-blinded, placebo controlled, double-crossover trial of up to 120 patients having received MC-1 at doses of 100, 300 or 1,000 mg or placebo, given alone and in combination with a 20-mg dose of an ACE Inhibitor. The crossover study design will provide information on the effectiveness of MC-1 alone and in combination with an ACE Inhibitor for eight weeks in each treatment regimen, for a total treatment period of 16 weeks per patient. This study will assess MC-4232's effect on several important parameters in diabetic hypertensive patients, including glycated hemoglobin (HbA1c), triglycerides and blood pressure.